News
-
According to Tiziana Life Sciences, The ALS Association will award a Lawrence & Isabel Barnett Drug Development Program Grant to the Ann Romney Center for Neurologic Diseases at the Brigham and Women’s Hospital (BWH) for… Read more . . .
-
Shortly after Savara announced the resignation of Badrul Chowdhury as its Chief Medical Officer, Philip Morris International (PMI) has announced the appointment of Chowdhury as PMI’s new Chief Life Sciences Officer, Smoke-Free Products, effective in… Read more . . .
-
Nebulizer developer Respira Technologies, which recently announced the appointment of Brian Quigley as CEO, has changed its name to “Qnovia,” the company said. No reason for the name change was announced, but the previous name… Read more . . .
-
Bryn Pharma said that it has completed a pivotal study of its Utuly (BRYN-NDS1C) epinephrine nasal spray comparing PK/PD profiles of Utuly to a 0.3 mg dose of epinephrine delivered by autoinjector. According to the… Read more . . .
-
Device maker Nemera has announced the opening of its new headquarters building in Lyons, France. According to the company, the new BREEAM-certified building will also be home to the company’s European innovation teams. Nemera also… Read more . . .
-
According to CanSino Biologics, China’s National Medical Products Administration (NMPA) has approved the company’s Convidecia Air nebulized COVID-19 vaccine as a booster dose. In December 2021, CanSino Bio announced a deal with Aerogen for the… Read more . . .
-
Vistagen Therapeutics has announced that it will restart the Phase 3 PALISADE-2 trial of PH94B aloradine nasal spray for the treatment of anxiety in social anxiety disorder (SAD), which the company had paused after the… Read more . . .
-
According to Bharat Biotech, Indian regulators have cleared its iNCOVACC (BBV154) intranasal vaccine against COVID-19 for use in adults aged 18 and older under a Restricted Use in Emergency Situation. Following the approval, Bharat Bio… Read more . . .
-
FluGen has announced that a Phase 1b age de-escalation clinical trial of its M2SR intranasal live virus flu vaccine has completed enrollment of the first cohort, which includes children aged 9-17. The study will subsequently… Read more . . .
-
Illiad Biotechnologies has closed a $42.8 million financing round, the company said, with the funds intended to support a Phase 2b challenge study of the company’s BPZE1 intranasal pertussis vaccine as well as other development… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany